PMEF
CHRS icon

Point72 Middle East FZE’s Coherus Oncology CHRS Stock Holding History

Point72 Middle East FZE’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-190,823
Closed -$635K – 246
2023
Q4 		$635K Buy
+190,823
New +$511K 0.02% 746
2023
Q3 		– Sell
-54,500
Closed -$233K – 1500
2023
Q2 		$233K Buy
54,500
+53,044
+3,643% +$313K 0.01% 1010
2023
Q1 		$9.96K Buy
+1,456
New +$11.3K ﹤0.01% 1484

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Point72 Middle East FZE's CHRS Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 190,823 shares — an estimated $635K sold.

Point72 Middle East FZE first reported a position in CHRS in Q1 2023 and held it in 3 quarters. The position peaked at $635K in Q4 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 190,823 Coherus Oncology shares in Q1 2024, an estimated $635K.
  • Point72 Middle East FZE first reported a position in Coherus Oncology in Q1 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's Coherus Oncology position peaked at $635K in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.